Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation The HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) Score by Lip, Gregory Y.H. et al.
A
s
F
H
C
S
f
d
t
A
G
Journal of the American College of Cardiology Vol. 57, No. 2, 2011
© 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
PComparative Validation of a Novel
Risk Score for Predicting Bleeding Risk
in Anticoagulated Patients With Atrial Fibrillation
The HAS-BLED (Hypertension, Abnormal Renal/Liver Function,
Stroke, Bleeding History or Predisposition, Labile INR,
Elderly, Drugs/Alcohol Concomitantly) Score
Gregory Y. H. Lip, MD,* Lars Frison, PHD,† Jonathan L. Halperin, MD,‡ Deirdre A. Lane, PHD*
Birmingham, England; Mölndal, Sweden; and New York, New York
Objectives The purpose of this study was to investigate predictors of bleeding in a cohort of anticoagulated patients and to
evaluate the predictive value of several bleeding risk stratification schemas.
Background The risk of bleeding during antithrombotic therapy in patients with atrial fibrillation (AF) is not homogeneous,
and several clinical risk factors have been incorporated into clinical bleeding risk stratification schemas. Current
risk stratification schemas for bleeding during anticoagulation therapy have been based on complex scoring sys-
tems that are difficult to apply in clinical practice, and few have been derived and validated in AF cohorts.
Methods We investigated predictors of bleeding in a cohort of 7,329 patients with AF participating in the SPORTIF (Stroke
Prevention Using an ORal Thrombin Inhibitor in Atrial Fibrillation) III and V clinical trials and evaluated the pre-
dictive value of several risk stratification schemas by multivariate analysis. Patients were anticoagulated orally
with either adjusted-dose warfarin (target international normalized ratio 2 to 3) or fixed-dose ximelagatran
36 mg twice daily. Major bleeding was centrally adjudicated, and concurrent aspirin therapy was allowed in
patients with clinical atherosclerosis.
Results By multivariate analyses, significant predictors of bleeding were concurrent aspirin use (hazard ratio [HR]: 2.10; 95%
confidence interval [CI]: 1.59 to 2.77; p  0.001); renal impairment (HR: 1.98; 95% CI: 1.42 to 2.76; p  0.001);
age 75 years or older (HR: 1.63; 95% CI: 1.23 to 2.17; p  0.0008); diabetes (HR: 1.47; 95% CI: 1.10 to 1.97; p 
0.009), and heart failure or left ventricular dysfunction (HR: 1.32; 95% CI: 1.01 to 1.73; p  0.041). Of the tested
schemas, the new HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposi-
tion, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score performed best, with a stepwise increase in rates of ma-
jor bleeding with increasing HAS-BLED score (ptrend 0.0001). The c statistic for bleeding varied between 0.50 and
0.67 in the overall entire cohort and 0.68 among patients naive to warfarin at baseline (n  769).
Conclusions This analysis identifies diabetes and heart failure or left ventricular dysfunction as potential risk factors for bleeding
in AF beyond those previously recognized. Of the contemporary bleeding risk stratification schemas, the new HAS-
BLED scheme offers useful predictive capacity for bleeding over previously published schemas and may be simpler
to apply. (J Am Coll Cardiol 2011;57:173–80) © 2011 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.09.024a
c
g
A
t
t
A
i
strial fibrillation (AF) is associated with a substantial risk of
troke and systemic embolism. Thromboprophylaxis with oral
rom the *University of Birmingham Centre for Cardiovascular Sciences, City
ospital, Birmingham, England; †AstraZeneca R&D, Mölndal, Sweden; and ‡The
ardiovascular Institute, Mount Sinai Medical Center, New York, New York. The
PORTIF III and V studies were sponsored by AstraZeneca. Dr. Lip has received
unding for research, educational symposia, consultancy, and lecturing from
ifferent manufacturers of drugs used for the treatment of atrial fibrillation and
hrombosis, including AstraZeneca, Boehringer, Nayer, Pfizer/BMS, Biotronic,
stellas, Sanofi, Cardiome, and Merck; and is a clinical advisor to the UK NICE
uidelines on AF management, and a task force member of the 2010 ESC anticoagulation (OAC) is most effective in reducing stroke
ompared with antiplatelet therapy (1,2). Compared with
uidelines and ACCP9 writing committee. Dr. Frison is an employee of
straZeneca. Dr. Halperin has received consulting fees from several pharmaceu-
ical manufacturers involved in the development of novel oral anticoagulants for
he prevention of thromboembolism in patients with atrial fibrillation, including
straZeneca, the sponsor of the SPORTIF trials. Dr. Lane has received an
nvestigator-initiated educational grant from Bayer Healthcare, and has received
ponsorship to attend meetings from AstraZeneca.Manuscript received May 11, 2010; revised manuscript received August 18, 2010,
ccepted September 6, 2010.
b
r
l
r
s
w
h
r
a
r
i
s
a
e
S
h
(
p
t
c
b
a
p
m
s
f
C
y
i
p
r
b
A
F
b
E
s
p
n
p
n
f
s
p
u
v
F
t
p
A
x
r
t
d
P
T
n
w
h
r
o
w
I
a
l
(
m
a
a
d
f
a
p
e
c
s
o
b
i
p
e
t
i
H
a
s
p
w
u
i
w
174 Lip et al. JACC Vol. 57, No. 2, 2011
Bleeding Risk in Atrial Fibrillation: A Clinical Dilemma January 11, 2011:173–80OAC, antiplatelet therapy confers
a smaller benefit for stroke preven-
tion (1,2) and is associated with
similar rates of major bleeding,
particularly among elderly patients
with AF (3).
See page 181
Given that increasing numbers
of patients with AF will be
treated with OAC, attention has
een directed toward estimation of both stroke and bleeding
isk to guide the selection of the most appropriate prophy-
actic measures. Accurate estimation of stroke and bleeding
isks is difficult (4), leading to the development of various
troke risk stratification schemas to help identify subjects
ho may benefit most from OAC therapy because of their
igher intrinsic risk of stroke (5). Like the thromboembolic
isk of patients with AF, the risk of bleeding during
nticoagulation is not homogeneous, and various clinical
isk factors have been identified that are associated with
ncremental bleeding risk. Current schemes for bleeding risk
tratification by Shireman et al. (6), Gage et al. (7) (with the
cronym HEMORR2HAGES), Beyth et al. (8), and Kuijer
t al. (9) have been difficult to apply in clinical practice.
ome use complex scoring systems (6,9), and only a few
ave been derived (and validated) in patients with AF
7,10), with others derived from general anticoagulated
opulations that may have different clinical profiles from
hose of AF patients (who are often older with more
omorbidities and polypharmacy) (8).
Thus, contemporary guidelines simply list risk factors for
leeding and given the lack of a simple, pragmatic, widely
ccepted method for bleeding risk assessment applicable to
atients with AF, no specific schema is currently recom-
ended for routine clinical use (11). It is recognized that
everal risk factors predisposing to bleeding are also risk
actors for stroke (12), and although some schemas (e.g.,
HADS2 [congestive heart failure, hypertension, age 75
ears, diabetes mellitus and previous stroke or transient
schemic attack (doubled)] [13]) have modest value for
redicting stroke, they are very good at predicting a patient’s
isk of bleeding (14,15).
We recently derived and validated the HAS-BLED
leeding risk schema for AF (also called the Birmingham
F bleeding schema: Hypertension, Abnormal Renal/Liver
unction, Stroke, Bleeding History or Predisposition, La-
ile INR, Elderly, Drugs/Alcohol Concomitantly) in a
uropean cohort (16). The predictive accuracy of this
chema was good in the overall population, especially when
atients were treated with antiplatelet agents alone or with
o antithrombotic therapy, but further validation and com-
arison with other published bleeding risk schemas are
Abbreviations
and Acronyms
AF  atrial fibrillation
CI  confidence interval
HR  hazard ratio
INR  international
normalized ratio
LV  left ventricular
OAC  oral anticoagulationecessary. rThe objective of this analysis was to determine risk factors
or bleeding and compare the performance of bleeding risk
tratification schemas in a large cohort of anticoagulated AF
atients in a contemporary clinical trial. To achieve this, we
sed the combined dataset of the SPORTIF (Stroke Pre-
ention Using an ORal Thrombin Inhibitor in Atrial
ibrillation) III and V trials, which compared warfarin with
he oral direct thrombin inhibitor ximelagatran for the
revention of stroke and systemic embolism in patients with
F at moderate to high risk of stroke (17,18). Although
imelagatran was not inferior to well-controlled warfarin in
educing the risk of stroke and systemic embolism in these
rials (17,18), concerns about liver safety led to the with-
rawal of ximelagatran from further clinical development.
atients and Methods
he SPORTIF III and V clinical trials were designed as
oninferiority phase III trials comparing ximelagatran with
arfarin in patients with nonvalvular AF at moderate to
igh risk of thromboembolism, and a pooled analysis of the
esults of both trials was pre-specified. SPORTIF III was an
pen-label trial in 23 countries (17), whereas SPORTIF V
as a double-blind trial conducted in North America (18).
nclusion criteria for both trials were similar and included
ge 18 years and older, persistent or paroxysmal AF, and at
east 1 of the following stroke risk factors: hypertension
defined as high blood pressure requiring antihypertensive
edication, but below 180/100 mm Hg at randomization),
ge 75 years and older, previous stroke, transient ischemic
ttack or systemic embolic event; left ventricular (LV)
ysfunction (ejection fraction 40% or symptomatic heart
ailure), age 65 years and older with coronary artery disease,
nd age 65 years and older with diabetes mellitus. End
oints were evaluated in a blinded manner by a central
vents adjudication committee.
We initially investigated predictors of bleeding risk in the
ombined SPORTIF III and V trial cohort of 7,329
ubjects. Major bleeding was defined as fatal or clinically
vert bleeding associated with either transfusion of 2 U of
lood or 20 g/l decrease in hemoglobin or bleeding
nvolving a critical anatomic site other than the brain
arenchyma. Intracerebral bleeding counted as primary
fficacy events. Clinically overt bleeding not satisfying cri-
eria for major bleeding was classified as minor bleeding.
We then tested the predictive value of several bleed-
ng risk schemas in this cohort: Shireman et al. (6),
EMORR2HAGES (7), Beyth et al. (8), Kuijer et al. (9),
nd HAS-BLED (16) (Table 1). For each risk stratification
chema, we calculated the c statistic as a measure of
redictive accuracy. In the HEMORR2HAGES scheme,
e considered blood pressure 160 mm Hg systolic as
ncontrolled hypertension, a history of malignancy as sim-
lar to current malignancy, alcohol consumption of 20 U
eekly as ethanol abuse creatinine clearance 50 ml/min asenal disease, a low platelet count as less than the lower limit
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January 11, 2011:173–80 Bleeding Risk in Atrial Fibrillation: A Clinical Dilemmaf normal, and hemoglobin content less than the lower limit
f normal as anemia. Relevant genetic and laboratory data
required for calculation of some schemes), apart from
erum creatinine and hematocrit, were not available for the
PORTIF AF cohort. For HAS-BLED, labile INR was
efined as 60% time in the therapeutic range (INR 2 to 3
nclusive), concomitant platelet inhibitor agents as aspirin or
onsteroidal anti-inflammatory drugs (clopidogrel was not
llowed in the trial), elderly older than 75 years of age, given
hat the majority of patients (76%) in the cohort were older
han 65 years of age. In addition, we report the c statistics
n subgroups of individuals who were warfarin naive at
aseline as well as those taking warfarin plus aspirin
oncurrently.
tatistical analysis. Categorical data were evaluated with
he Fisher exact test or the chi-square test for 2 categories
nd continuous data using Student t test. All tests were
erformed 2-tailed, with p values 0.05 considered statis-
ically significant. No adjustment was made for multiple
esting because all reported results are explorative. Annual-
zed event rates assume constant rates over time. Unless
therwise stated, all analyses were performed on pooled data
rom the SPORTIF III and V trial cohorts. All randomized
atients were included in the intention-to-treat population.
n on-treatment analysis accounted for time until therapy
as interrupted for up to 30 consecutive days (or up to 60
ays for cardioversion) or 60 days cumulatively. Assessment
f major bleeding used the on-treatment approach. Given
he wide range of time in the studies for individual patients
common study closure, intended duration of study treat-
ent ranging between 12 and 26 months), statistical anal-
ses had to take time at risk into account; this was done
ither through Cox regression analyses or by using patient-
ears as analyses unit. All analyses on major bleeding in this
aper are based on on-treatment analyses (17,18). Patients
re contributing with time at risk as long as they are
eceiving study treatment (according to the on-treatment
ontemporary Bleeding Risk Stratification SchemasTable 1 Contemporary Bleeding Risk Stratification Schemas
Low Moderate High
Kuijer et al.,
1999 (9)
0 1–3 3 (1.6  a
and 0
Beyth et al.,
1998 (8)
0 1–2 3 Age 6
diabe
Gage et al.,
2006 (7)
0–1 2–3 4 HEMOR
coun
(CYP
previ
Shireman et al.,
2006 (6)
1.07 1.07–2.19 2.19 (0.49 
(0.71
drug
Pisters et al.,
2010 (16)
0 1–2 3 HAS-BLE
Histo
maxi
TOH  ethyl alcohol; GI  gastrointestinal; Hct  hematocrit; INR  international normalized raefinition) or until they experienced major bleeding. Pa- (ients were not censored for reasons other than major
leeding or study drug discontinuation.
Univariate Cox regression modeling was used to estimate
he hazard ratios (HRs) and 95% confidence intervals for
ndividual risk factors with major bleeding as the dependent
ariable. All potential risk factors investigated in the uni-
ariate analyses were included in the multivariate Cox
egression analyses; only those variables with p values that
emained significant at the 5% level in the presence of
ther selected variables were retained in the final model.
-statistics were estimated to quantify the predictive accu-
acy of the risk schemes, with 95% confidence intervals
btained by bootstrapping analyses. The Hosmer-
emeshow test for calibration was also performed whenever
c-statistic was calculated. All analyses were performed
sing SAS statistical software (version 8.2, SAS Institute,
nc., Cary, North Carolina). More detailed descriptions of
he analytical methods used for the SPORTIF III and V
rials are published elsewhere (17,18).
esults
aseline characteristics of AF patients with known status
egarding major bleeding during follow-up are summarized
n Table 2. Patients in the whole cohort experiencing major
leeding events (n  217) were more often elderly (p 
.0001), nonsmokers (p 0.016) with diabetes (p 0.018),
V dysfunction (p  0.018), previous stroke or transient
schemic attack (p  0.0001), and impaired renal function
p  0.0001). As expected, those with bleeding events had
higher mean CHADS2 score than those without bleeding
vents (p  0.0001).
Among the 7,329 patients, 79% were previously receiving
itamin K antagonist treatment, whereas 21% were vitamin
antagonist naive. Among those previously receiving vita-
in K antagonist treatment, 46% had their AF diagnosed
5 years ago, 16% between 1 and 5 years, and the
emaining 38% within the preceding year. The overall mean
Calculation of Bleeding Risk Score
(1.3  sex)  (2.2  cancer) with 1 point for age 60 yrs, female or malignancy,
e
GI bleed in past 2 weeks, previous stroke, comorbidities (recent MI, Hct 30%,
eatinine 1.5 ml/l) with 1 point for presence of each condition and 0 if absent
ES score: liver/renal disease, ETOH abuse, malignancy, age 75 yrs, low platelet
ction, rebleeding risk, uncontrolled hypertension, anemia, genetic factors
isk of fall or stroke, with 1 point for each risk factor present with 2 points for
ed
70 yrs)  (0.32  female)  (0.58  remote bleed)  (0.62  recent bleed) 
ohol/drug abuse)  (0.27  diabetes)  (0.86  anemia)  (0.32  antiplatelet
ith 1 point for presence of each, and 0 if absent
re: Hypertension, Abnormal Renal/Liver Function (1 point each), Stroke, Bleeding
redisposition, Labile INR, Elderly Drugs/Alcohol concomitantly (1 point each);
points
 myocardial infarction.ge) 
if non
5 yrs,
tes, cr
R2HAG
t or fun
2C9), r
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age 
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Bleeding Risk in Atrial Fibrillation: A Clinical Dilemma January 11, 2011:173–80as 499 (196) days; the corresponding results for patients
ithout and with major bleeding were 503 (194) days and
80 (217) days, respectively.
aseline Characteristics of Atrial Fibrillationti nts With Known Foll w-up Status Regardingajor Bleeding
Table 2
B seline Characteris ics of Atrial Fibrillation
Patients With Known Follow-up Status Regarding
Major Bleeding
Characteristic
Bleeding Event
(n  234)
No Bleed
(n  7,095) p Value
Age, yrs, mean (SD) 73.9 (8.6) 70.9 (8.9) 0.0001
65 196 (84) 5,349 (75) 0.0031
75 125 (53) 2,679 (38) 0.0001
Female sex 73 (31) 2,184 (31) 0.89
Body mass index, kg/m2 28.7 (6.6) 29.0 (5.8) 0.50
AF type
Duration since first diagnosed (yrs) 6.4 (5.9) 6.3 (7.1) 0.91
Paroxysmal 26 (11) 810 (12) 1.00
Persistent/permanent 208 (89) 6,282 (88) 1.00
Medical history
Hypertension 180 (77) 5445 (77) 1.00
Diabetes mellitus 67 (29) 1658 (23) 0.071
Coronary artery disease 117 (50) 3162 (45) 0.11
LV dysfunction 102 (44) 2579 (36) 0.027
Stroke/TIA 61 (26) 1478 (21) 0.060
SEEs 8 (3) 320 (5) 0.52
CHADS2 score, mean (SD) 2.6 (1.2) 2.2 (1.2) 0.0001
Bleeding risk factors
Previous clinically significant bleed 19 (8) 441 (6) 0.22
SBP at entry, mean (SD) 136 (19) 135 (18) 0.48
CrCl 50 ml/min 57 (24) 885 (13) 0.0001
Alcohol use 97 (41) 3,230 (46) 0.23
Smoking 11 (5) 667 (9) 0.011
alues shown are n (%) unless otherwise indicated.
AF  atrial fibrillation; CHADS2  congestive heart failure, hypertension, age 75 years,
iabetes mellitus and previous stroke or transient ischemic attack (doubled); CrCl  creatinine
learance; LV  left ventricular; SEEs  systemic embolic events; SBP  systolic blood pressure;
IA  transient ischemic attack.
isk Factors for Major Bleeding by Univariate and Multivariate AnaTable 3 Risk Factors for Major Bleeding by Univariate and Mul
Risk Factor
Event Rate
(%/Patient-Year)
Risk Factor Present
Yes No HR
Aspirin use 3.94 1.94 2.02
CrCl 50 ml/min 4.91 2.01 2.48
Age 75 yrs 3.42 1.73 1.97
Diabetes mellitus 2.95 2.17 1.36
LV dysfunction 2.85 2.07 1.37
Smoking 1.20 2.47 0.49
Previous stroke or TIA 3.05 2.18 1.40
Coronary artery disease 2.65 2.11 1.25
Clinically significant bleeding 3.15 2.30 1.36
Alcohol abuse 2.14 2.53 0.84
Statin use 2.08 2.48 0.84
Female 2.41 2.32 1.04
Hypertension 2.36 2.33 1.01Only factors associated with p  0.05 in the presence of other selected variables were retained in the fi
CI  confidence interval; HR  hazard ratio; other abbreviations as in Table 2.Univariate and multivariate analyses of risk factors pre-
ictive of major bleeding are shown in Table 3. By univar-
ate analysis, significant predictors of bleeding were concur-
ent aspirin use, reduced creatinine clearance (50 ml/min),
dvanced age (75 years and older), diabetes mellitus, LV
ysfunction, smoking, and previous stroke or transient
schemic attack. By multivariate analysis, significant predic-
ors of bleeding were aspirin use (p 0.001), renal impairment
p  0.001), age 75 years and older (p  0.0008), diabetes
p  0.0089), and LV dysfunction (p  0.041).
In Table 4, rates of major bleeding by HAS-BLED score
re presented for the entire cohort and for patients assigned
o warfarin therapy. c-statistics for prediction of major
leeding were similar (0.66 and 0.67; ptrend 0.0001 for
oth). The relationship between the individual components of
he HAS-BLED scheme and clinical bleeding events is shown
n Tables 5 and 6. Labile INR, advanced age, concomitant
spirin or nonsteroidal anti-inflammatory drug use were con-
istently predictive of major bleeding in this cohort.
Comparison of contemporary bleeding risk stratification
chemas revealed variable classification of AF patients into
arious bleeding risk strata (Table 7). In this analysis, there
as no significant difference in c statistics between patients
n the warfarin arms compared with those in the ximelagat-
an arms of the SPORTIF trials. Among those treated with
arfarin, the HAS-BLED scheme exhibited a marginally
etter c-statistic value (0.67) than the other 4 schemas
valuated, with the lowest c-statistic (0.50) associated with
he scheme of Kuijer et al. (9). The HAS-BLED scheme
lassified 20.4% of the cohort into the low-risk category,
ith a bleeding rate of 1% per year, whereas subjects
lassified as low risk by the other schemes had higher
leeding rates (1.9% per year). Among patients who were
arfarin naive at entry (n  769) and in those treated with
ate Analyses
nivariate Analyses Multivariate Analyses*
CI)† p Value HR (95% CI)† p Value
2.65) 0.0001 1.92 (1.40–2.51) 0.0001
3.35) 0.0001 1.90 (1.38–2.62) 0.0001
2.55) 0.0001 1.71 (1.30–2.25) 0.0001
1.80) 0.035 1.36 (1.03–1.81) 0.033
1.77) 0.017 1.31 (1.01–1.70) 0.043
0.89) 0.019
1.87) 0.024
1.62) 0.083
2.18) 0.19
1.09) 0.20
1.11) 0.22
1.37) 0.79
1.37) 0.94lysestivari
U
(95%
(1.54–
(1.84–
(1.53–
(1.02–
(1.06–
(0.26–
(1.04–
(0.97–
(0.85–
(0.65–
(0.63–
(0.79–
(0.75–nal model. †HR (95% CI) derived by Cox regression modeling.
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January 11, 2011:173–80 Bleeding Risk in Atrial Fibrillation: A Clinical Dilemmaarfarin plus aspirin concurrently (n  772), the HAS-
LED schema displayed the highest c-statistic values (0.68
nd 0.60, respectively) of the 5 risk schemas evaluated.
We also tested, with multivariate Cox regression models,
hether the new score adds significantly to models already
ncorporating the 4 older scores 1 at a time. In all 4
nstances, HAS-BLED was associated with p  0.0001
hen inserted into models already incorporating the older
cores. In contrast, none of the other 4 older scores added
ignificantly when inserted 1 at a time into a model already
ncluding HAS-BLED (full data not shown). The Hosmer-
emeshow test for calibration was also performed in con-
unction with all c statistics reported in Tables 7 and 8.
one of the p values were 0.05 for any of the risk scores
i.e., lack of goodness of fit was not indicated). For HAS-
LED, for example, the p values were 0.24 for all patients
nd 0.13 for the warfarin patient cohort. For the schema by
hireman et al. (6) (the only one with a p value 0.1), the
value was 0.075 for the warfarin patients (and 0.29 for all
atients) (complete data not shown).
There was a progressive increase in the HR for bleeding
rom the low-risk to moderate-risk stratum and from the
isk Factors for Major Bleeding According to the HAS-BLED Score:Table 5 Risk Factors for Major Bleeding According to the HAS
Risk Factor
SPORTIF III/V
Cohort Definition
Risk Factors
Present,
n (%)
With Risk Fac
n (%)
Hypertension SBP 160 mm Hg at entry 533 (7.3) 19 (3.6)
Abnormal renal function* CrCl 50 ml/min 942 (12.9) 57 (6.0)
Stroke before entry Yes/no 918 (12.5) 35 (3.8)
Bleeding history History of clinically
significant bleeding
460 (6.3) 19 (4.1)
Labile INR TTR 60% 1,235 (33.7) 65 (5.3)
Elderly Age 75 yrs at entry 2,441 (33.3) 116 (4.8)
Age 65 yrs at entry 5,545 (75.7) 196 (3.5)
Drugs† Aspirin or NSAID 3,051 (41.6) 136 (4.5)
Alcohol Alcohol20 U/week 204 (2.8) 6 (2.9)
Aspirin use Aspirin at any time 1,578 (21.5) 80 (5.1)
NSAID NSAID at any time 1,956 (26.7) 89 (4.6)
ajor Bleeding Rates by HAS-BLED Score in the Overall SPORTIF Cnd Those Taking Warfarin Only (n  3,665)Table 4 Major Bleeding Rates by HAS-BLED Score in the Overaand Those Taking Warfarin Only (n  3,665)
HAS-BLED
Score
Patients With Particular Score
in the Whole Cohort*
Major Bleed
Events†
0 1,757 (24.0) 21 (1.2)
1 2,717 (37.1) 75 (2.8)
2 1,752 (23.9) 63 (3.6)
3 834 (11.4) 50 (6.0)
4 241 (3.3) 23 (9.5)
5 27 (0.4) 2 (7.4)
6 1 (0.0) 0
c-statistic  0.654; p value for trend 0.0001
alues are n (%). *Percentage of column total. †Percentage of row total.
HAS-BLED  Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisp
hrombin Inhibitor in Atrial Fibrillation.Abnormal liver function was an exclusion criterion for these studies. †Concomitant use of clopidogrel w
NSAID  nonsteroidal anti-inflammatory drug; other abbreviations as in Tables 1, 2, 3, and 4.oderate-risk to the high-risk stratum according to the
AS-BLED scheme (Table 8) that was less apparent with
he other bleeding risk schemas.
iscussion
his analysis of the performance of various bleeding risk
tratification schemas over 11,000 patient-years of anti-
oagulation exposure confirms the predictive value of pre-
iously identified risk factors, including advanced patient
ge, concomitant use of aspirin or nonsteroidal anti-
nflammatory drugs during anticoagulation use, and renal
mpairment. In addition, the data identify associations of
iabetes mellitus and clinical heart failure or LV systolic
ysfunction with an increased risk of bleeding during
herapeutic anticoagulation in this particular cohort of
atients with AF. Of the various risk stratification schemas
valuated, the HAS-BLED schema more accurately dis-
riminated patients on the basis of bleeding risk, based on
he magnitude of the c statistic.
Risk factors for bleeding with OAC have largely been
erived from cohort studies or secondary analyses of clinical
le Cohort (n  7,329)Score: Whole Cohort (n  7,329)
Bleeding
Univariate Analyses Multivariate Analyses
Without Risk Factors,
n (%) HR (95% CI) p Value HR (95% CI) p Value
215 (3.2) 1.14 (0.71–1.82) 0.59 1.10 (0.69–1.76) 0.70
177 (2.8) 2.48 (1.84–3.35) 0.0001 1.77 (1.28–2.44) 0.0005
199 (3.1) 1.32 (0.92–1.89) 0.13 1.24 (0.87–1.78) 0.23
215 (3.1) 1.36 (0.85–2.18) 0.19 1.31 (0.82–2.09) 0.26
71 (2.9) 2.14 (1.53–2.99) 0.0001 2.05 (1.54–2.74) 0.0001
118 (2.4) 2.10 (1.63–2.72) 0.0001 1.76 (1.34–2.33) 0.0001
38 (2.1) 1.74 (1.23–2.47) 0.0017
98 (2.3) 1.92 (1.48–2.49) 0.0001 1.85 (1.43–2.40) 0.0001
228 (3.2) 1.00 (0.44–2.25) 1.00 1.11 (0.49–2.51) 0.80
154 (2.7) 2.02 (1.54–2.65) 0.0001
145 (2.7) 1.58 (1.21–2.06) 0.0007
t (n  7,329)ORTIF Cohort (n  7,329)
Patients With Particular Score Among
Those Taking Warfarin Only*
Major Bleeding
Events†
746 (20.4) 7 (0.9)
1,283 (35.0) 44 (3.4)
950 (25.9) 39 (4.1)
483 (13.2) 28 (5.8)
180 (4.9) 16 (8.9)
22 (0.6) 2 (9.1)
1 (0.0) 0
c-statistic  0.659; p value for trend 0.0001
, Labile INR, Elderly, Drugs/Alcohol Concomitantly; SPORTIF  Stroke Prevention Using an ORalWho-BLED
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F populations identified advanced age, uncontrolled hy-
ertension, ischemic heart disease, cerebrovascular disease,
nemia, concomitant antiplatelet therapy, and previous
leeding as predictors of major bleeding events during
nticoagulation (19), and labile INR control, advanced
atient age, and concomitant aspirin or nonsteroidal anti-
nflammatory drug use have been consistently identified as
redictors in other analyses (10). Diabetes mellitus, con-
rolled hypertension, and sex were not significant risk
actors for bleeding in the systematic review forming the
asis for the UK-NICE clinical practice guidelines (19).
ther factors specifically associated with an incremental risk
f intracerebral hemorrhage during OAC include associated
isk Factors for Major Bleeding According to the HAS-BLED Score:Table 6 Risk Factors for Major Bleeding According to the HAS
Risk Factor
SPORTIF III/V
Cohort Definition
Risk Factors
Present,
n (%)
With Risk Fac
n (%)
Hypertension SBP 160 mm Hg at entry 260 (7.1) 7 (2.7)
Abnormal renal function* CrCl 50 ml/min 488 (13.4) 31 (6.4)
Stroke before entry Yes/no 450 (12.3) 18 (4.0)
Bleeding history History of clinically
significant bleeding
208 (5.7) 10 (4.8)
Labile INR TTR 60% 1,235 (33.7) 65 (5.3)
Elderly Age 75 yrs at entry 1,222 (33.3) 67 (5.5)
Age 65 yrs at entry 2,762 (75.4) 112 (4.1)
Drugs† Aspirin or NSAID 1,487 (40.6) 79 (5.3)
Alcohol Alcohol20 U/week 99 (2.7) 3 (3.0)
Aspirin use Aspirin at any time 772 (21.1) 50 (6.5)
NSAID NSAID at any time 954 (26.0) 50 (5.2)
Abnormal liver function was an exclusion criterion for these studies. †Concomitant use of clopid
Abbreviations as in Tables 1, 2, 3, 4, and 5.
redictive Value of Contemporary Bleeding Risk Schemas in Patienith the Whole Study Cohort and Subgroups of Warfarin-Naive PatiTable 7 Pr dictive Value of Contemporary Bleeding Risk Sch mWith the Whole Study Cohort and Subgroups of Warfar
Bleeding Risk Score
(Ref. #)
Warfarin Patients
(n  3,665)
Low Moderate High
c-S
(
HAS-BLED (16)
% in risk category 20.4 60.9 18.7
Bleeding events, n (%)† 7 (0.9) 83 (3.7) 46 (6.7) (0
Shireman et al. (6)
% in risk category 82.2 17.7 0.1
Bleeding events, n (%) 99 (3.3) 37 (5.7) 0 (0.0) (0
HEMORR2HAGES (7)
% in risk category 73.5 23.8 2.7
Bleeding events, n (%) 81 (3.0) 53 (6.1) 2 (2.0) (0.
Beyth et al. (8)
% in risk category 10.2 79.6 10.2
Bleeding events, n (%) 8 (2.1) 113 (3.9) 15 (4.0) (0.
Kuijer et al. (9)
% in risk category 9.0 85.7 5.3
Bleeding events, n (%) 11 (3.0) 120 (3.8) 5 (2.6) (0.All c-statistics have been calculated based on the entire range for each risk score. †Bleeding rates are
Abbreviations as in Tables 1, 3, and 4.erebrovascular disease and concomitant antiplatelet ther-
py; tobacco use or alcohol consumption; ethnicity; geno-
ype; certain vascular abnormalities, such as amyloid angi-
pathy, leukoaraiosis, and microbleeds detected by brain
maging; and possibly genetic variations (20). Thus, the
leeding risk associated with diabetes mellitus and clinical
eart failure or LV systolic dysfunction in anticoagulated
F populations requires further study.
Of note, many of the risk factors for anticoagulation-
elated bleeding are also indications for the use of antico-
gulants in AF patients (10,14,15,19). Patients in whom
ajor bleeding complications developed during anticoagu-
ation therapy had a higher mean CHADS2 score than
hose without bleeding, consistent with previous observa-
farin Patients Only (n  3,665)Score: Warfarin Patients Only (n  3,665)
Bleeding
Univariate Analyses Multivariate Analyses
Without Risk Factors,
n (%) HR (95% CI) p Value HR (95% CI) p Value
129 (3.8) 0.69 (0.32–1.47) 0.34 0.65 (0.30–1.39) 0.27
105 (3.3) 2.15 (1.44–3.21) 0.0002 1.46 (0.95–2.26) 0.085
118 (3.7) 1.17 (0.71–1.92) 0.53 1.12 (0.68–1.84) 0.66
126 (3.6) 1.32 (0.69–2.51) 0.40 1.31 (0.68–2.49) 0.42
71 (2.9) 2.14 (1.53–2.99) 0.0001 2.06 (1.47–.89) 0.0001
69 (2.8) 2.07 (1.48–2.89) 0.0001 1.82 (1.27–2.62) 0.0012
24 (2.7) 1.57 (1.01–.44) 0.044
57 (2.6) 2.06 (1.47–2.90) 0.0001 1.96 (1.39–2.76) 0.0001
133 (3.7) 0.89 (0.28–2.78) 0.84 1.00 (0.32–3.17) 0.99
86 (3.0) 2.39 (1.69–3.39) 0.0001
86 (3.2) 1.59 (1.12–2.25) 0.0093
as not allowed.
king Warfarin Comparedand Those Taking Warfarin Plus AspirinPatients Taking W rfarin Compared
ive Patients and Those Taking Warfarin Plus Aspirin
c-Statistic* (95% CI)
ic*
I)
All Patients
(n  7,329)
Warfarin-Naive
Patients at Baseline
(n  769)
Patients Taking
Warfarin  Aspirin
(n  772)
0.65 (0.61–0.68) 0.66 (0.55–0.74) 0.60 (0.53–0.68)
0)
0.64 (0.61–0.68) 0.61 (0.52–0.71) 0.58 (0.51–0.66)
7)
0.62 (0.58–0.65) 0.62 (0.52–0.72) 0.58 (0.51–0.66)
5)
0.57 (0.53–0.60) 0.50 (0.44–0.57) 0.52 (0.46–0.57)
0)
0.49 (0.46–0.52) 0.44 (0.38–0.51) 0.49 (0.45–0.55)
6)War-BLED
Major
tors,ts Taentsas in
in-Na
tatist
95% C
0.66
.61–0.7
0.63
.58–0.6
0.61
56–0.6
0.56
51–0.6
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January 11, 2011:173–80 Bleeding Risk in Atrial Fibrillation: A Clinical Dilemmaions (14,15). It has been suggested that the CHADS2
troke risk stratification and the HEMORR2HAGES
leeding risk scores are so closely correlated that they
lassify two-thirds of patients into similar risk strata for
emorrhagic and ischemic events, casting doubt on the
linical utility of combining the 2 schemas (21).
The available bleeding risk stratification schemas classify
ariable proportions of AF patients into low-, moderate-,
nd high-risk categories. In this respect, the HAS-BLED
chema displayed better predictive power than the 4 other
ested bleeding risk stratification methods for bleeding
vents among patients in the combined SPORTIF III and
cohort, as well as for those randomized to the adjusted-
ose arms, the subgroup who were warfarin naive at entry
nd those taking aspirin concurrently with warfarin, based
n comparative c statistics.
Optimum selection of patients with AF for anticoagulant
herapy depends not only on assessment of their intrinsic
isk of thromboembolism but also on identification of those
t increased risk of the development of bleeding complica-
ions. Even in patients at moderate or intermediate risk of
troke, accurate identification of those at low risk of bleed-
ng may guide a preference for anticoagulation over aspirin,
iven additional data showing that anticoagulation may be
he better option for stroke prevention (22), with a net
linical benefit (even when considering potential bleeding
isk) in favor of anticoagulation rather than antiplatelet
herapy. Of patients enrolled in the SPORTIF trials by
irtue of at least 1 stroke risk factor other than AF,
pproximately 1 in 5 were in the low-risk category for
leeding based on the HAS-BLED criteria, and major
leeding occurred at a rate of 1% per year in these cases
uring treatment. In contrast, patients classified as low risk
y the other 4 schemas experienced higher rates of bleeding
azard Ratios (95% Confidence Interval) of Risktegories for the 5 Blee ing Risk Stratificat onch mas Among Warfarin Pati nts (n  3,665)
Table 8
Hazard Ratios (95% Confidence Interval) of Risk
Categories for the 5 Bleeding Risk Stratification
Schemas Among Warfarin Patients (n  3,665)
Schema (Ref. #)
Moderate vs.
Low
High vs.
Moderate
High vs.
Low
HAS-BLED (16)
HR (95% CI) 4.31 (1.99–9.33) 2.02 (1.41–2.90) 8.56 (3.86–18.98)
p value 0.0002 0.0001 0.0001
Shireman et al. (6)
HR (95% CI) 1.87 (1.28–2.72) — —
p value 0.0012
HEMORR2HAGES (7)
HR (95% CI) 2.19 (1.55–3.10) 0.34 (0.08–1.38) 0.75 (0.18–3.06)
p value 0.0001 0.13 0.69
Beyth et al. (8)
HR (95% CI) 1.87 (0.91–3.82) 1.10 (0.64–1.89) 2.07 (0.88–4.90)
p value 0.09 0.73 0.096
Kuijer et al. (9)
HR (95% CI) 1.17 (0.63–2.16) 0.67 (0.27–1.64) 0.78 (0.27–2.24)
p value 0.63 0.38 0.64
bbreviations as in Tables 3, 4, and 7.1.9% per year) during the same period. There was a trogressive increment in HR for bleeding from the lowest to
ighest risk strata delineated by the HAS-BLED schema,
ut this gradient was not verified for the other scales tested.
These findings in a large clinical trial cohort are broadly
omparable to those in the initial validation of HAS-BLED
n 3,000 patients with AF in the Euro Heart survey
ollowed for 1 year (16). In that analysis, the HAS-BLED
chema also displayed predictive accuracy (c-statistic 
.72), outperforming other bleeding risk schemas in AF
atients treated with platelet inhibitor drugs or without
ntithrombotic therapy (c-statistic  0.91 and 0.85, respec-
ively), indicating that bleeding risk estimated by this
ethod is not confined to anticoagulated patients. Whether
leeding risk estimated by this method will also apply to
atients treated with newer anticoagulant drugs, such as
abigatran, rivaroxaban, apixaban, and edoxaban currently
nder development for stroke prevention in patients with
F, has not been evaluated. Estimation of bleeding risk will
ikely be important with these new agents even if they show
fficacy superior or noninferior to that of warfarin and
imilar or lower rates of major bleeding because prophylactic
herapy could potentially be applied more broadly across the
atient population at risk (22).
With particular reference to dabigatran, 2 doses of which
ere compared with warfarin in the RE-LY (Randomized
valuation of Long-Term Anticoagulation Therapy) trial
23), the availability of an accurate bleeding risk assessment
ool could potentially prove valuable in dose selection for
ndividual patients if combined with stroke risk assessment.
lthough it is appealing to think that the HAS-BLED
chema could be effectively applied in this context, further
alidation of its predictive value for bleeding in relation to
abigatran dose would be necessary if the compound were
pproved and brought to market for routine clinical use.
tudy limitations. Assessment of bleeding risk is compli-
ated by variation in the criteria used to define major,
linically relevant nonmajor and minor bleeding events,
lthough these have been more uniform in recent trials than
n earlier studies (24). Furthermore, bleeding rates and risk
actors derived from clinical trial populations in which
atients are carefully selected according to specific research
rotocols, anticoagulated using standard drug supply sources
nd monitored with stable thromboplastin reagents by
edicated personnel according to rigid criteria, may differ
rom those in clinical practice. Also, many of the patients
ere not warfarin naive and bleeding risk prediction might
e much better if it took into account the time-specific
ontext of treatment, including when warfarin was started
nd recent experience (e.g., in the past month) with anti-
latelet drugs and INR control, and whether it predicted
isk of bleeding in the next month (rather than on average
ver the course of therapy); however, the addition of these
ariables would introduce such complexity and reduce prac-
ical utility for everyday clinical use.
Advancing age is a continuous variable linearly related to
he risks of stroke and bleeding (19). In the clinical trial
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Bleeding Risk in Atrial Fibrillation: A Clinical Dilemma January 11, 2011:173–80ohort that formed the basis for this report, 75% of
articipants were older than 65 years of age and the elderly
riterion for the HAS-BLED schema was taken as age 75
ears and older at study entry. Setting this threshold at age
5 years would have a small effect on the results (shifting the
statistic from 0.67 to 0.65 for the 3,665 patients assigned
o warfarin). Bleeding in elderly patients with AF is more
elated to biological age rather than chronological age and is
ften multifactorial, being affected by comorbidity, antico-
gulation intensity and lability, and frequent changes in
oncomitant pharmacology (10,19,21). Also, in comparing
he different prediction schemas, it is important to recognize
hat some include only risk factors that could be known at
he time of starting warfarin, whereas 2 schemas (HAS-
LED and that of Shireman et al. [6]) include time-
ependent risk factors. The HAS-BLED score already
ccounts for some of these variables, enhancing its predic-
ive value as a cumulative assessment of bleeding risk.
onclusions
his analysis identifies diabetes and LV dysfunction as
otential clinical correlates of bleeding in an anticoagulated
linical trial cohort of patients with nonvalvular AF. The
AS-BLED score may be a useful assessment of bleeding
isk in AF patients in everyday clinical practice.
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